---
title: Elucigene partners with Congenica on new NGS cystic fibrosis kit
description: Elucigene partners with Congenica on new NGS cystic fibrosis kit
image: https://blog.congenica.com/hubfs/Elucigene.jpg
---

- [Our Customers and Partners](http://www.congenica.com/our-customers)
- [Our Product Portfolio](http://www.congenica.com/congenica-products) 
    - **Inherited Diseases** 
          - [Rare Disease](http://www.congenica.com/congenica-rare-disease)
          - [Inherited Cancer](http://www.congenica.com/congenica-inherited-cancer)
          - [Prenatal Health](http://www.congenica.com/congenica-prenatal)
          - [Carrier Screening](http://www.congenica.com/congenica-carrier-screening)
          - [Neurodevelopmental Disorders](http://www.congenica.com/congenica-neuro)
    - **Somatic Oncology** 
          - [Solid Tumours](http://www.congenica.com/congenica-oncology)
    - **Pathogen** 
          - [Pathogen Surveillance](http://www.congenica.com/congenica-pathogen-surveillance)
- [Our Services](http://www.congenica.com/congenica-services) 
    - [Clinical Interpretation Services](http://www.congenica.com/congenica-clinical-interpretation-services)
    - [Professional Services](http://www.congenica.com/professional-services)
    - [Customer Support](http://www.congenica.com/customer-support)
    - [Pharma Services](http://www.congenica.com/pharma-services)
- Resources 
    - [Publications](http://www.congenica.com/publications)
    - [Supporting materials](http://www.congenica.com/resources)
    - [News](https://blog.congenica.com/)
    - [Events and webinars](http://www.congenica.com/events-webinars)
- [About us](http://www.congenica.com) 
    - [Leadership Team](http://www.congenica.com/leadership)
    - [Quality](http://www.congenica.com/quality)
    - [Investors](http://www.congenica.com/investors)
    - [People and Vacancies](http://www.congenica.com/people)
- [Contact us](http://www.congenica.com/contact)

Login

##### Please select your location and reference genome:

[America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/)

[Overview](https://blog.congenica.com) [Elucigene partners with Congenica on new NGS cystic fibrosis kit](https://blog.congenica.com/2016/12/01/elucigene-partners-congenica-cystic-fibrosis-kit)

![Elucigene partners with Congenica on new NGS cystic fibrosis kit](https://blog.congenica.com/hubfs/Elucigene.jpg)

 News

# Elucigene partners with Congenica on new NGS cystic fibrosis kit

 12/1/2016     |    0 min read

**Accurate variant analysis facilitates personalised care pathways**

The emergence of new therapies that treat the causes of cystic fibrosis is creating an imperative for more accurate variant analysis. To address this demand [Elucigene Diagnostics](http://www.elucigene.com/), a leading developer and distributor of prenatal and human genetics diagnostics, in partnership with Congenica, a leader in genomic analysis and interpretation has developed a new NGS cystic fibrosis kit.

The “all-in-one” CFTR gene analysis kit allows sample processing, analysis with next generation sequencing (NGS) and variant interpretation streamlining the diagnostic process.

Dr Mark Street-Docherty, Commercial Manager for Elucigene Diagnostics says: “Congenica has produced a bespoke analysis and reporting pipeline to support customers using our new targeted NGS kit for cystic fibrosis (CFTR) gene analysis.

“The Congenica and Elucigene partnership will provide support to CFTR diagnostics, reporting only clinically relevant information, and therefore simplifying analysis associated with competitor whole genome approaches.

“Congenica’s [Sapientia](https://www.congenica.com/products-and-services/)TM platform will form part of our offering to the customer, enabling seamless sample processing and analysis.”

Craig Taylor, Head of Business Development for Congenica, says: “We’re very excited about partnering with Elucigene and introducing Sapientia to clinical labs around the world, enabling them to benefit from the same interpretation and analysis platform employed by leading NHS Hospitals in the UK. This partnership illustrates the flexibility of Sapientia, which can be customized according to partner needs.”

Cystic fibrosis is an inherited disorder affecting 70,000 people worldwide. The new product is the first in Elucigene’s range to embrace Next Generation Sequencing (NGS). Elucigene has developed probes specifically designed to deeply sequence, with higher confidence, the areas of the CFTR gene where the targeted variants occur. This has increased the detection rate from between 85 to 95 per cent to over 99 per cent for some populations.

The test uses a bespoke version of Sapientia, including a bioinformatics pipeline that filters out non-pathogenic mutations and returns the pathogenic variant. Once the variant is identified, scientific literature regarding the consequences of that exact mutation on the patient’s phenotype and condition is made readily accessible through the platform for clinicians to consult.

Bringing this new kit to Elucigene’s international customer base will provide a better picture of the distribution of the variants within different populations, allowing the development of personalised medicine.

---

<http://www.facebook.com/share.php?u=https://blog.congenica.com/2016/12/01/elucigene-partners-congenica-cystic-fibrosis-kit&utm_medium=social&utm_source=facebook> <http://www.linkedin.com/shareArticle?mini=true&url=https://blog.congenica.com/2016/12/01/elucigene-partners-congenica-cystic-fibrosis-kit&utm_medium=social&utm_source=linkedin> <https://twitter.com/intent/tweet?original_referer=https://blog.congenica.com/2016/12/01/elucigene-partners-congenica-cystic-fibrosis-kit&utm_medium=social&utm_source=twitter&url=https://blog.congenica.com/2016/12/01/elucigene-partners-congenica-cystic-fibrosis-kit&utm_medium=social&utm_source=twitter&source=tweetbutton&text=>

### Related articles

![SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/hs-fs/hubfs/New%20logos/Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png?width=320&height=192&name=Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png)

 9/2/2025

#### [SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/seqone-acquires-congenica-to-create-a-global-leader-in-ai-powered-genomic-medicine)

Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries

![Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/hs-fs/hubfs/male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg?width=320&height=192&name=male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg)

 11/6/2024

#### [Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/congenica-showcased-in-recently-launched-genomics-spotlight-2024-report)

We are thrilled to announce that Congenica is one of the companies showcased in the recently launched Genomics Spotlight 2024 report produced by the UK Department for Business and Trade (DBT).

![Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/hs-fs/hubfs/Onco%20.png?width=320&height=192&name=Onco%20.png)

 6/19/2024

#### [Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/congenica-named-best-genomic-data-analysis-software-company-2024-by-ghp)

We are thrilled to announce that Congenica has been awarded the title of "Best Genomic Data Analysis Software Company 2024" by Global Health & Pharma Magazine. 

##### Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory.

- [Privacy Policy](http://www.congenica.com/privacy-policy)
- [Cookie Policy](http://www.congenica.com/cookie-policy)

<https://twitter.com/congenica> <https://en-gb.facebook.com/congenica/> <https://www.linkedin.com/company/congenica/> 

Log in to Congenica

##### Please select your location and reference genome:

[America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/)

![CE](https://blog.congenica.com/hs-fs/hubfs/CE.png?width=80&height=80&name=CE.png) ![ISO-27001](https://blog.congenica.com/hs-fs/hubfs/ISO-27001.jpg?width=80&height=80&name=ISO-27001.jpg) ![TR-Testmark_9000030872_EN_2024_CMYK](https://blog.congenica.com/hs-fs/hubfs/2023%20website%20images/TR-Testmark_9000030872_EN_2024_CMYK.png?width=80&height=80&name=TR-Testmark_9000030872_EN_2024_CMYK.png) ![HIPAA Compliant](https://blog.congenica.com/hs-fs/hubfs/HIPAA%20Compliant.png?width=80&height=80&name=HIPAA%20Compliant.png)

Copyright © 2026 Congenica Ltd. Company number: 8273616 Registered in England and Wales.